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Plan of the lecture 
1. hemophilia    
Definition 
Epidemiology 
Risk Factors and etiology 
Mechanisms, classification 
Clinical presentation 
Complications  
Diagnosis, treatment  
Prognosis, prophylaxis 
Abbreviations, diagnostic guidelines  
https://www.hemophilia.org/Bleeding-Disorders/Types-of-Bleeding-Disorders  
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Hemophilia (HL): 
definition 1 
HL is a group of a sex-linked hereditary genetic 
disorders that occurs almost exclusively in males and 
impairs the body's ability to control blood clotting, 
which is used to stop bleeding when a blood vessel is 
broken even after minor injuries 
Types:  
• HL A (clotting factor VIII deficiency)  is a recessive X-
linked most common form of the disorder which  
occurs in 1 in 5,000–10,000 male births  
http://www.merriam-webster.com/dictionary/hemophilia https://en.wikipedia.org/wiki/Haemophilia  
http://emedicine.medscape.com/article/955690-overview    
Hemophilia (HL): 
definition 2 
HL is a group of a sex-linked hereditary genetic 
disorders that occurs almost exclusively in males and 
impairs the body's ability to control blood clotting, 
which is used to stop bleeding when a blood vessel is 
broken even after minor injuries 
Types:  
• HL B (factor IX deficiency)  is a recessive X-linked 
form of the disorder which occurs in 1 in 20,000–
34,000 male births   
http://www.merriam-webster.com/dictionary/hemophilia https://en.wikipedia.org/wiki/Haemophilia  
http://emedicine.medscape.com/article/955690-overview    
Hemophilia (HL): 
definition 3 
HL is a group of a sex-linked hereditary genetic 
disorders that occurs almost exclusively in males and 
impairs the body's ability to control blood clotting, 
which is used to stop bleeding when a blood vessel is 
broken even after minor injuries 
Types:  
• HL C  or plasma thromboplastin antecedent (PTA) 
deficiency or Rosenthal syndrome (factor XI 
deficiency) is an autosomal (i.e. not X-linked) 
genetic disorder which occurs in both sexes  
http://www.merriam-webster.com/dictionary/hemophilia https://en.wikipedia.org/wiki/Haemophilia  
http://emedicine.medscape.com/article/955690-overview    
Hemophilia (HL): 
epidemiology   
Global distribution of bleeding disorders (a) and HL A (c) in 
five countries reporting the highest number of patients (b) 
and (d) show s that nearly 5 and 9% of global patients with 
bleeding disorders and HL A are from India 
http://www.ijmr.org.in/article.asp?issn=0971-5916;year=2014;volume=140;issue=1;spage=19;epage=31;aulast=Kar  
Hemophilia (HL): 
epidemiology   
Distribution by age for patients with HL A&B  
http://www.revhematologia.sld.cu/index.php/hih/article/view/145/118  
Hemophilia (HL): 
risk factors and etiology 1 
• Risk factors for HL include family history of bleeding 
and almost  always being male 
• HL is caused by an inherited X-linked recessive trait, 
with the defective gene located on the X 
chromosome 
• Males have only one X chromosome, and if the 
factor VIII gene or if the factor IX gene is missing on 
a boy's X chromosome, he will have HL A or HL B  
http://emedicine.medscape.com/article/955690-overview   
https://www.nlm.nih.gov/medlineplus/ency/article/000538.htm  
Hemophilia (HL): 
risk factors and etiology 2 
• If a woman has a defective factor VIII gene or a 
defective factor  IX gene, she is considered a carrier: 
boys born to such women have a 50% chance of 
having hemophilia A or hemophilia B, and their 
daughters have a 50% chance of being a carrier  
http://emedicine.medscape.com/article/955690-overview   
https://www.nlm.nih.gov/medlineplus/ency/article/000538.htm  
Hemophilia (HL): 
risk factors and etiology 3 
• HL C with deficiency of factor XI was described first 
in 2 sisters and a maternal uncle of an American 
Jewish family after bled from dental extractions;  
unlike the bleeding tendency in HL A or HL B, which 
is clearly related to the factor level, the bleeding risk 
in HL C is not always influenced by the severity of 
the deficiency, especially in individuals with partial 
deficiency  
• All female children of men with HL carry the 
defective gene  
 
http://emedicine.medscape.com/article/955690-overview   
https://www.nlm.nih.gov/medlineplus/ency/article/000538.htm  
Hemophilia (HL): 
risk factors and etiology 
http://www.moh.gov.sa/en/HealthAwareness/EducationalContent/Diseases/Hematology/Pages/006.aspx  
Hemophilia (HL): 
mechanisms 1 
Normal blood clotting is a complex process requiring as many 
as 20 clotting factors. The deficiency or absence of one of 
these factors may disrupt the clotting process 
http://www.ihtc.org/medical-professionals/blood-disorders/bleeding-disorders/hemophilia-a-and-b/  
Hemophilia (HL): 
mechanisms 2 
Diagram showing how in hemophilia patients, blood cannot 
clot properly because of poor platelet plug 
http://www.koate-dviusa.com/about-hemophilia-a-pages-13.php  
Hemophilia (HL):  
clinical presentation 1 
• All symptom of HL are related to uncontrolled or unexpected bleeding, either 
externally (e.g. skin cut, nosebleed) or internally (e.g. knee, muscle, brain) 
• The extent of bleeding depends on the amount of functional clotting factors 
present in the body; when the amount of clotting factor is low, bleeding symptoms 
become more severe 
• Internal bleeding into the joints, muscle and brain is serious and requires 
immediate medical attention 
• The following bleeding symptoms are associated with HL: 
• Excessive bleeding following minor injuries (e.g. skin cut) 
• Large skin bruises from bleeding within the skin 
• Uncontrolled bleeding after receiving a shot or pulling a tooth 
• Frequent nosebleeds that are hard to stop 
• Blood in the urine or stool 
• Pain and swelling in the joints due to internal bleeding 
• Infantile bleeding after birth or circumcision 
• Headaches and difficulties with vision 
http://www.innerbody.com/diseases-conditions/hemophilia  
 
 
Hemophilia (HL): 
severity classification  1 
• HL is classified as mild, moderate, or severe 
depending on the amount of the clotting factor 
present in a person’s blood 
• The normal range of FVIII and FIX is between 50% 
and 150% 
http://www.ihtc.org/medical-professionals/blood-disorders/bleeding-disorders/hemophilia-a-and-b/  
Hemophilia (HL): 
severity classification  2 
• Mild: bleeding occur after injury, trauma, or 
surgery; the condition may have very few 
symptoms otherwise - 25% of the HL population 
• Moderate: bleeding episodes tend to occur after 
minor injuries, spontaneous bleeding episodes 
may occur - 15% of the HL population 
• Severe: in addition to bleeding after injury, 
trauma, or surgery, severe hemophilia 
characterized by spontaneous bleeding into 
joints and muscles - 60% of the HL population 
 http://www.ihtc.org/medical-professionals/blood-disorders/bleeding-disorders/hemophilia-a-and-b/  
Hemophilia (HL): 
severity classification  3 
http://www.ihtc.org/medical-professionals/blood-disorders/bleeding-disorders/hemophilia-a-and-b/  
Severity Blood clotting factor level 
Normal 50%-150% 
Mild hemophilia 6%-49% 
Moderate 
hemophilia 
1%-5% 
Severe hemophilia <1% 
Hemophilia (HL): 
clinical presentation 2 
 Frequency and sites of bleeding in patients with 
severe and moderate HL A 
http://www.ijmr.org.in/article.asp?issn=0971-5916;year=2014;volume=140;issue=1;spage=19;epage=31;aulast=Kar  
 
 
Hemophilia (HL):  
clinical presentation 3 
• Bleeding may occur anywhere in the body 
• The most serious sites of bleeding are joints, 
muscles, digestive tract and brain 
• Muscle and joint haemorrhages (hemarthrosis) are 
indicative of hemophilia, while digestive tract and 
cerebral haemorrhages are also germane to other 
coagulation disorders 
• Though typically not life-threatening, joint bleeds 
are one of the most serious symptoms of HL  
https://en.wikipedia.org/wiki/Haemophilia  
 
 
Hemophilia (HL):  
clinical presentation 4 
• Repeated bleeds into a joint capsule can cause 
permanent joint damage and disfigurement 
resulting in chronic arthritis and disability 
• Joint damage is not a result of blood in the capsule 
but rather the healing process 
• When blood in the joint is broken down by enzymes 
in the body, the bone in that area is also degraded  
https://en.wikipedia.org/wiki/Haemophilia  
 
 
Hemophilia (HL):  
clinical presentation 5 
Symptoms, Topic and Severity of HL 
http://www.ihtc.org/medical-professionals/blood-disorders/bleeding-disorders/hemophilia-a-and-b/  
 
 
 
 
Topic 
Severity of HL 
Severe Moderate Mild 
Cause of 
bleeding 
Spontaneous 
Minor trauma, 
spontaneous 
Major trauma, 
surgery 
Frequency 
of bleeding 
2 – 4/month 4 – 6/year Uncommon 
Pattern of 
bleeding 
Joint, soft tissue +/- bleeding after circumcision, +/- 
neonatal intracranial hemorrhage, bleeding with 
surgical procedures 
Hemophilia (HL): 
complications 1 
Complications may be both directly from the disease 
or from its treatment: 
• Deep internal bleeding, e.g. deep-muscle bleeding, 
leading to swelling, numbness or pain of a limb 
• Joint damage from hemarthrosis (hemophilic 
arthropathy), potentially with severe pain, 
disfigurement, and even destruction of the joint 
and development of debilitating arthritis  
https://en.wikipedia.org/wiki/Haemophilia  
 
 
Hemophilia (HL): 
complications 2 
• Transfusion transmitted infection from blood 
transfusions that are given as treatment 
• Adverse reactions to clotting factor treatment, 
including the development of an immune inhibitor 
which renders factor replacement less effective 
• Intracranial hemorrhage is a serious medical 
emergency caused by the buildup of pressure inside 
the skull, that can cause disorientation, nausea, loss 
of consciousness, brain damage, and death 
https://en.wikipedia.org/wiki/Haemophilia  
 
 
Hemophilia (HL): 
complications 3 
http://www.obizur.com/images/hemo-bleed.png  http://hubpages.com/health/Bleeding-Disorders-Due-To-Deficiency-Of-Coagulation-Factors-Hemophilia-A-Factor-VIII-deficiency#  
http://www.hemophiliabangalore.org/images/gall-2.jpg  https://i.ytimg.com/vi/hzb_RHk0-fI/hqdefault.jpg  http://pocketdentistry.com/25-congenital-bleeding-and-hypercoagulable-disorders/ 
 
HL bleedings 
Hemophilia (HL): 
diagnosis 1 
• Personal history of bleeding 
• Family history of bleeding and its inheritance 
pattern 
• Laboratory evaluation 
• Genetic testing to determine an individual's risk of 
attaining or passing on HL 
https://en.wikipedia.org/wiki/Hodgkin%27s_lymphoma  
 
 
Hemophilia (HL): 
diagnosis 2 
Laboratory Evaluation 
• In a patient with suspected HL, screening coagulation tests along with mixing 
studies are performed 
• The activated partial thromboplastin time (aPTT) assay evaluates the intrinsic 
pathway of coagulation and is quite often prolonged in patients with HL 
• If the aPTT is prolonged, a mixing study is performed to evaluate the correction 
of a patient’s aPTT with a pooled plasma from healthy donors 
• In patients with coagulation factor deficiencies, the aPTT is corrected in a 1:1 
mixing study 
• If a factor deficiency is suspected, then specific factor assays such as FVIII and 
FIX levels are performed to diagnose the type and severity of the deficiency  
• In patients with mild hemophilia, the aPTT assay may be normal 
• Once the diagnosis of HL is established, the screening of other at-risk family 
members, including females, should be performed to diagnose other affected 
individuals and determine the clotting factor level of carriers  
http://www.ihtc.org/medical-professionals/blood-disorders/bleeding-disorders/hemophilia-a-and-b/  
 
 
Hemophilia (HL): 
treatment 1  
• Treatment is comprehensive and focused on 
preserving both physical health and quality of life of 
individuals with the disorder 
• The primary goal of treatment is the prevention or 
cessation of bleeding episodes 
• Prompt treatment of acute bleeding episodes is 
essential to minimize long-term complications 
• Both nonpharmacologic and pharmacologic 
strategies are used in the treatment  
http://formularyjournal.modernmedicine.com/formulary-journal/news/clinical/clinical-pharmacology/hemophilia-etiology-complications-and-current-  
 
 
Hemophilia (HL): 
treatment 2  
Nonpharmacologic therapy consists of supportive 
care 
• Rest, ice, compression, and elevation (RICE) are 
important measures for treatment of joint or 
muscle bleeding episodes 
• Splints, crutches, or casts can be used to allow the 
affected joint or muscle to rest after a bleeding 
episode 
• Cold or ice compresses should be applied for 20 
minutes every 4 to 6 hours  
 en.wikipedia.org/wiki/Haemophilia  formularyjournal.modernmedicine.com/formulary-journal/news/clinical/clinical-pharmacology/hemophilia-etiology-complications-and-current-  
 
 
Hemophilia (HL): 
treatment 3  
Pharmacologic strategies 
• HL can be controlled with regular infusions of the 
deficient clotting factor (VIII in HL A or IX in HL B) 
• Some patients develop antibodies against the 
replacement factors, so them non-human products 
must be given, such as porcine factor VIII 
• If a patient becomes refractory to replacement 
coagulation factor, this may be partially overcome 
with recombinant human factor VII   
en.wikipedia.org/wiki/Haemophilia formularyjournal.modernmedicine.com/formulary-journal/news/clinical/clinical-pharmacology/hemophilia-etiology-complications-and-current-  
 
 
Hemophilia (HL): 
treatment 4  
Treatment regimens 
• Optimal therapy for patients with severe HL A or B 
involves regular administration of clotting factor 
concentrates, often 2 to 3 times per week, to 
increase the factor level to a moderate range (> 1%) 
to prevent bleeding 
• Episodic Infusion (on-demand) treatment is defined 
as utilization of clotting factor concentrates in 
response to an acute bleeding episode to stop 
bleeding after it has started  
http://www.ihtc.org/medical-professionals/blood-disorders/bleeding-disorders/hemophilia-a-and-b/  
 
 
Hemophilia (HL): 
treatment 5  
New approaches (gene therapy) 
• On 10 December 2011, a team of British and 
American investigators reported the successful 
treatment of HL B using gene therapy; they inserted 
the F9 gene into an adeno-associated virus-8 vector, 
which has a propensity for the liver, where factor 9 
is produced, and remains outside the chromosomes 
so as not to disrupt other genes; the transduced 
virus was infused intravenously; to prevent 
rejection, the patients were primed with steroids to 
suppress their immune response  
https://en.wikipedia.org/wiki/Haemophilia  
 
 
Hemophilia (HL): 
treatment 6 
New approaches (gene therapy) 
• In October 2013, the Royal Free London National 
Health Society Foundation Trust in London reported 
that after treating six people with HL in early 2011 
with the genetically modified adeno-associated 
virus, over two years later all were still producing 
blood plasma clotting factor 
https://en.wikipedia.org/wiki/Haemophilia  
 
 
Hemophilia (HL): 
treatment 7  
Contraindication  
• Anticoagulants and nonsteroidal antinflammatory 
drugs are contraindicated for people with HL as 
these can aggravate clotting difficulties 
• Contraindicated are activities with a high likelihood 
of trauma, such as motorcycling and skateboarding, 
American football, hockey, boxing, wrestling, 
rugby,  soccer, baseball, and basketball 
https://en.wikipedia.org/wiki/Haemophilia  
 
 
Hemophilia (HL): 
prognosis 
• People with severe HL who don't receive adequate, 
modern treatment have greatly shortened lifespans 
and often do not reach maturity 
• Prior to the 1960s average life expectancy was only 
11 years 
• By the 1980s average life expectancy was was 50–
60 years 
• Today with appropriate treatment an average 
lifespan in people with severe HL is approximately 
10 years shorter than an unaffected people  
https://en.wikipedia.org/wiki/Haemophilia  
 
 
Hemophilia (HL): 
prophylaxis 
Patients are advised to 
• Stay up-to-date on vaccinations 
• Attend annual comprehensive clinic evaluations 
• Avoid situations and activities that cause bleeding 
• Maintain good oral hygiene (to prevent extensive 
dental procedures) 
• Exercise regularly and maintain a healthy body 
weight  
http://www.ihtc.org/medical-professionals/blood-disorders/bleeding-disorders/hemophilia-a-and-b/  
Hemophilia (HL): 
abbreviations  
• ACS        - acute coronary syndrome 
• aPCC    - activated prothrombin complex  
• aPTT     - activated partial thromboplastin time 
• ITI           - immune tolerance induction 
• HL         - Hemophilia 
• NS           - nephrotic syndrome 
• PCI         - percutaneous coronary intervention 
• pPTA     - plasma thromboplastin antecedent 
• rFVIIa    - recombinant activated Factor VII 
Hemophilia (HL): 
diagnostic and treatment guidelines 
• Guidelines for the Management of Hemophilia 
• WFH Treatment Guidelines - World Federation of Hemophilia 
• Consensus recommendations for the diagnosis and treatment of acquired 
hemophilia A 
• Diagnosis & Treatment Guidelines for Bleeding Management 
• Haemophilia - Diagnosis - Guidelines - Best Practice 
 
Plan of the lecture 
2. thrombocytopenic purpura (TP)   
Definition 
Epidemiology, classification 
Risk factors, etiology 
Mechanisms, classification 
Clinical presentation 
Complications, diagnosis, treatment  
Prognosis, prophylaxis 
Abbreviations, diagnostic guidelines  
http://www.b12patch.com/blog/wp-content/uploads/2012/04/20283gk35b095o5.jpg  
Thrombocytopenic purpura (TP):  
definition  
Thrombocytopenic purpura (TP) is purpura associated 
with a reduction in circulating blood platelets which 
can result from a variety of causes  
 en.wikipedia.org/wiki/Thrombotic_thrombocytopenic_purpura en.wikipedia.org/wiki/Idiopathic_thrombocytopenic_purpura en.wikipedia.org/wiki/Thrombocytopenic_purpura  
Thrombocytopenic purpura (TP):  
types 1 
Type 1 
• Immune TP (primary immune thrombocytopenia, 
primary immune TP or autoimmune TP), in most 
cases is immune-mediated and is defined as 
isolated low platelet count with normal bone 
marrow   
 en.wikipedia.org/wiki/Thrombotic_thrombocytopenic_purpura en.wikipedia.org/wiki/Idiopathic_thrombocytopenic_purpura en.wikipedia.org/wiki/Thrombocytopenic_purpura  
Thrombocytopenic purpura (TP):  
types 2 
Type 2   
• Thrombotic TP (acquired - Moschcowitz syndrome, 
genetically inherited - Upshaw–Schulman syndrome), 
is a rare disorder of the blood-coagulation system, 
arising from inhibition or dysfunction of 
the enzyme ADAMTS13, and causing extensive 
microscopic clots (thrombi) to form in the small 
blood vessels throughout the body 
 
 
 en.wikipedia.org/wiki/Thrombotic_thrombocytopenic_purpura en.wikipedia.org/wiki/Idiopathic_thrombocytopenic_purpura en.wikipedia.org/wiki/Thrombocytopenic_purpura  
Thrombocytopenic purpura (TP):   
epidemiology  1 
• The incidence of Immune TP is estimated at 50–100 
new cases per million people per year, with children 
accounting for half of that amount 
• At least 70% of childhood cases will end up in 
remission within six months, even without 
treatment 
• A third of the remaining chronic cases will usually 
remit during follow-up observation, and another 
third will end up with only mild thrombocytopenia 
(defined as a platelet count above 50,000)  
https://en.wikipedia.org/wiki/Idiopathic_thrombocytopenic_purpura#Pathogenesis  
Thrombocytopenic purpura (TP):   
epidemiology  2 
• Immune TP is usually chronic in adults and the 
probability of durable remission is 20–40% 
• The male to female ratio in the adult group varies 
from 1:1.2 to 1.7 
• The mortality rate due to chronic Immune TP varies 
but tends to be higher relative to the general 
population for any age range 
• No significant difference was noted in the rate of 
survival between males and females  
https://en.wikipedia.org/wiki/Idiopathic_thrombocytopenic_purpura#Pathogenesis  
Thrombocytopenic purpura (TP):   
epidemiology  3 
• The incidence of Thrombotic TP is about 4-5 cases 
per million people per year 
• Idiopathic Thrombotic TP occurs more often in 
women and people of African descent 
• Thrombotic TP secondary to autoimmune 
disorders occurs more frequently in people of 
African descent  
• Untreated, Thrombotic TP has a mortality rate of as 
high as 90%  
https://en.wikipedia.org/wiki/Thrombotic_thrombocytopenic_purpura#Unknown_cause  http://emedicine.medscape.com/article/206598-overview#a6  
Thrombocytopenic purpura (TP):   
epidemiology  4 
• With plasma exchange, the mortality rate is reduced 
to 10-20% 
• Acute morbidities include ischemic events such as 
stroke, transient ischemic attacks, myocardial 
infarction and arrhythmia, bleeding, and azotemia 
• TTP during pregnancy may precipitate fetal loss 
• Relapses are not uncommon, occurring in 13-36% of 
patients 
https://en.wikipedia.org/wiki/Thrombotic_thrombocytopenic_purpura#Unknown_cause  http://emedicine.medscape.com/article/206598-overview#a6  
Thrombocytopenic purpura (TP):   
epidemiology  3 
Immune TP incidence rates according to age and sex  
 www.bloodjournal.org/content/94/3/909?sso-checked=true  
Thrombocytopenic purpura (TP):   
risk factors and etiology 1   
Immune TP  
• The acute form often follows an infection and has a 
spontaneous resolution within 2 months 
• The chronic form persists longer than 6 months 
with a specific cause being unknown 
• Immune TP can be triggered by drugs, or associated 
with infection, pregnancy, or immune disorders 
such as systemic lupus erythematosus, but about 
half of all cases are classified as "idiopathic," 
meaning the cause is unknown  
 en.wikipedia.org/wiki/Idiopathic_thrombocytopenic_purpura  medicinenet.com/script/main/art.asp?articlekey=24151  
Thrombocytopenic purpura (TP):   
risk factors and etiology 2   
Thrombotic TP 
• Acquired forms arise from inhibition of 
the enzyme ADAMTS13, a metalloprotease 
responsible for cleaving large multimers of von 
Willebrand factor (vWF) into smaller units with 
increased platelet adhesion to areas 
of endothelial injury  
• Genetically inherited form arising from dysfunction 
of ADAMTS13 with tendency for increased 
coagulation exists 
  en.wikipedia.org/wiki/Idiopathic_thrombocytopenic_purpura  medicinenet.com/script/main/art.asp?articlekey=24151  
Thrombocytopenic purpura (TP): 
mechanisms 1   
Immune TP  
• In 60% of cases, antibodies against platelet 
membrane glycoproteins IIb-IIIa or Ib-IX and 
the immunoglobulin G (IgG) type can be detected 
• The coating of platelets with IgG renders them 
susceptible to opsonization and phagocytosis 
by splenic macrophages, as well by Kupffer cells in 
the liver 
• The IgG autoantibodies are also thought to damage 
megakaryocytes    
 
en.wikipedia.org/wiki/Thrombotic_thrombocytopenic_purpura#Unknown_cause  en.wikipedia.org/wiki/Idiopathic_thrombocytopenic_purpura#Pathogenesis  
emedicine.medscape.com/article/206598-overview  
Thrombocytopenic purpura (TP): 
mechanisms 2   
Thrombotic TP 
• Thrombotic TP is characterized by clotting in small 
blood vessels, resulting in a low platelet count 
• In its full-blown form, the disease consists of the 
pentad of microangiopathic hemolytic anemia, 
thrombocytopenic purpura, neurologic 
abnormalities, fever, and renal disease 
• Reduced blood flow due to thrombosis and cellular 
injury results in end organ damage 
en.wikipedia.org/wiki/Thrombotic_thrombocytopenic_purpura#Unknown_cause  en.wikipedia.org/wiki/Idiopathic_thrombocytopenic_purpura#Pathogenesis  
emedicine.medscape.com/article/206598-overview  
Thrombocytopenic purpura (TP): 
mechanisms 3   
Mechanism of platelet destruction in Immune TP  
  
http://www.medscape.org/viewarticle/420904_6  
Thrombocytopenic purpura (TP): 
mechanisms 4   
Platelet autoantibody production in Immune TP   
  
http://4.bp.blogspot.com/_uiyskjNZYt8/TAevdJAWUSI/AAAAAAAABrU/cPJSHNFjl_g/s1600/Immune+thrombocytopenic+purpura.gif  
Thrombocytopenic purpura (TP): 
mechanisms 4   
Mechanisms of virus-induced thrombocytopenia  
http://www.frontiersin.org/files/Articles/124104/fimmu-05-00649-HTML/image_m/fimmu-05-00649-g001.jpg  
Thrombocytopenic purpura (TP): 
clinical presentation 1 
Immune TP 
• Bruising, petechiae, purpura 
• Prolonged bleeding from cuts 
• Spontaneous bleeding from nose 
• Bleeding gums, especially after dental work 
• Blood in urine or stools 
• Unusually heavy menstrual flow 
• Fatigue 
https://www.merckmanuals.com/professional/hematology-and-oncology/thrombocytopenia-and-platelet-dysfunction/immune-thrombocytopenia-(itp) 
http://www.mayoclinic.org/diseases-conditions/idiopathic-thrombocytopenic-purpura/basics/symptoms/con-20034239 http://emedicine.medscape.com/article/206598-overview   
Thrombocytopenic purpura (TP): 
clinical presentation 2 
Thrombotic TP  
• Bruising, petechiae, purpura, mucosal bleeding 
• Microangiopathic hemolytic anemia  
• Neurologic symptoms (hallucinations, bizarre 
behavior, delirium, stroke, hemiplegia, paresthesias, 
visual disturbance,  aphasia, headaches) 
• Kidney failure 
• Fever   
 https://www.merckmanuals.com/professional/hematology-and-oncology/thrombocytopenia-and-platelet-dysfunction/immune-thrombocytopenia-(itp) 
http://www.mayoclinic.org/diseases-conditions/idiopathic-thrombocytopenic-purpura/basics/symptoms/con-20034239 http://emedicine.medscape.com/article/206598-overview   
Thrombocytopenic purpura (TP):   
clinical presentation 3 
Petechiae and purpura in the skin 
http://www.skinerrors.com/wp-content/uploads/Idiopathic-thrombocytopenic-purpura.jpg  https://my.clevelandclinic.org/health/diseases_conditions/hic-immune-thrombocytopenia  
https://upload.wikimedia.org/wikipedia/commons/0/02/Oral_petechiae.JPG  http://www.primehealthchannel.com/idiopathic-thrombocytopenic-purpura.html  http://healthool.com/purpura/   
 
 
Thrombocytopenic purpura (TP): 
diagnosis  1 
Immune TP  
• The diagnosis is a process of exclusion and has to be 
determined that there are no blood abnormalities 
other than a low platelet count, and no physical 
signs other than bleeding; secondary causes should 
be excluded  
• Bone marrow examination is done if blood counts 
or blood smear reveals abnormalities in addition to 
thrombocytopenia, when clinical features are not 
typical, or if patients fail to respond to standard 
therapies emedicine.medscape.com/article/206598-overview en.wikipedia.org/wiki/Idiopathic_thrombocytopenic_purpura#Diagnosis  
merckmanuals.com/professional/hematology-and-oncology/thrombocytopenia-and-platelet-dysfunction/immune-thrombocytopenia-(itp)   
Thrombocytopenic purpura (TP): 
diagnosis  2 
 
 
Thrombotic TP  
• Measuring ADAMTS13 activity level 
• Laboratory studies: complete blood count and total 
white blood cell count is normal or slightly 
elevated, hemoglobin concentration is moderately 
depressed at 8-9 g/dL, platelet count generally 
ranges from 20,000-50,000/μL; coagulation 
studies, blood urea nitrogen, creatinine, serum 
bilirubin and lactate dehydrogenase as indirect 
measures of the degree of hemolysis  
emedicine.medscape.com/article/206598-overview en.wikipedia.org/wiki/Idiopathic_thrombocytopenic_purpura#Diagnosis  
merckmanuals.com/professional/hematology-and-oncology/thrombocytopenia-and-platelet-dysfunction/immune-thrombocytopenia-(itp)   
Thrombocytopenic purpura (TP): 
treatment 1  
Immune TP 1 
• There is no need to treat based on platelet counts 
• Current guidelines recommend treatment only in 
cases of significant bleeding 
• Initial treatment consists of corticosteroids, the 
dose and mode of administration is determined by 
platelet count and whether there is active bleeding 
•  In chronic refractory cases,  immunosuppresants 
( mycophenolate mofetil and azathioprine) and 
chemotherapy (vincristine) agent may be attempted  
https://en.wikipedia.org/wiki/Idiopathic_thrombocytopenic_purpura#Treatment https://en.wikipedia.org/wiki/Thrombotic_thrombocytopenic_purpura#Unknown_cause 
http://emedicine.medscape.com/article/206598-overview   
Thrombocytopenic purpura (TP): 
treatment 1  
Immune TP 2 
• Anti-RhD therapy for patients with certain blood 
types 
• Infusions of high-dose gamma globulin 
• Thrombopoietin receptor agonists (romiplostim, 
eltrombopag) that stimulate the bone marrow to 
make more platelets 
• Platelet transfusion is recommended in an 
emergency  
https://en.wikipedia.org/wiki/Idiopathic_thrombocytopenic_purpura#Treatment https://en.wikipedia.org/wiki/Thrombotic_thrombocytopenic_purpura#Unknown_cause 
http://emedicine.medscape.com/article/206598-overview   
Thrombocytopenic purpura (TP): 
treatment 2  
Thrombotic TP  
• The therapy of choice is plasma exchange with fresh 
frozen plasma 
• Another option, is intravenous administration of  
octaplas, a sterile, frozen solution of pooled human 
plasma from several donors as alternative to single-
donor plasma 
• Corticosteroids may also be used in refractory 
patients 
https://en.wikipedia.org/wiki/Idiopathic_thrombocytopenic_purpura#Treatment https://en.wikipedia.org/wiki/Thrombotic_thrombocytopenic_purpura#Unknown_cause 
http://emedicine.medscape.com/article/206598-overview   
Thrombocytopenic purpura (TP): 
prognosis  1 
Immune TP  
• With treatment, the chance of remission (a 
symptom-free period) is good 
• In rare cases, disease may become a long-term 
condition in adults and reappear, even after a 
symptom-free period 
https://www.nlm.nih.gov/medlineplus/ency/article/000535.htm https://en.wikipedia.org/wiki/Thrombotic_thrombocytopenic_purpura#Unknown_cause   
Thrombocytopenic purpura (TP): 
prognosis 2 
Thrombotic TP  
• The mortality rate is around 95% for untreated 
cases, but the prognosis is reasonably favorable 
(80–90% survival) for patients diagnosed and 
treated early with plasmapheresis 
https://www.nlm.nih.gov/medlineplus/ency/article/000535.htm https://en.wikipedia.org/wiki/Thrombotic_thrombocytopenic_purpura#Unknown_cause   
Thrombocytopenic purpura (TP): 
prophylaxis 
• There is no known way to prevent Immune TP and 
Thrombotic TP  
 
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0023094/  https://www.nlm.nih.gov/medlineplus/ency/article/000535.htm  
Thrombocytopenic purpura (TP): 
abbreviations  
• CBC  - complete blood count 
• IFA   - interferon-alpha   
• HIV   - human immunodeficiency virus  
• RA    - rheumatoid arthritis 
• SLE   - systemic lupus erythematosus  
• TP    - thrombocytopenic purpura 
• vWF - von Willebrand factor 
Thrombocytopenic purpura (TP): 
diagnostic and treatment guidelines 
• Diagnosis and treatment of idiopathic thrombocytopenic 
purpura: recommendations of the American Society of 
Hematology. The American Society of Hematology ITP Practice 
Guideline Panel. 
• Management of Immune Thrombocytopenic Purpura: An 
Update 
• Immune Thrombocytopenic Purpura 
• Guidelines on the diagnosis and management of thrombotic 
thrombocytopenic purpura and other thrombotic 
microangiopathies 
